Press Releases Otsuka Holdings Co., Ltd.

Equities

4578

JP3188220002

Pharmaceuticals

Delayed Japan Exchange Other stock markets 06:30:00 12/03/2026 GMT			5-day change	1st Jan Change
11,020.00 ^JPY	+1.29%		+8.36%	+24.20%

03-04	Irlab Working to Secure Funding for Phase 3 Study of Mesdopetam - fc	FW
02-26	Irlab Receives $3 Million Milestone Payment Following Dosing in Phase 1b Study	FW

Press Releases

01-14	Otsuka Holdings Submits Commitment Letter to Obtain Science-Based Targets Validation for the Entire Otsuka Group	AQ
31/10/24	Otsuka : Message from Tatsuo Higuchi, President and Representative Director, CEO	PU
31/10/24	Otsuka : Message from Makoto Inoue, Representative Director, COO	PU
08/02/24	Otsuka Group Selected for CDP Climate Change a List for a Second Consecutive Year	AQ
10/01/24	Otsuka Holdings Co., Ltd. - Donations to Support Relief Efforts Following the Noto Peninsula Earthquake	AQ
10/11/23	Recor Medical Announces U.S. Launch and First Commercial Cases of Paradise Ultrasound Renal Denervation Therapy	BU
08/11/23	Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension	BU
26/10/23	Recor Medical Announces Positive Results from Six-Month Pooled Analysis of Data from the RADIANCE Global Clinical Trial Program at TCT 2023	BU
23/08/23	Recor Medical and Otsuka Medical Devices Announce Positive Vote from U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on the Paradise™ Ultrasound Renal Denervation System for the Treatment of Hypertension	BU
27/04/23	Otsuka : Consolidated Financial Statements for the fiscal year ended December 31, 2022	PU
14/12/22	Otsuka Group Selected for CDP Climate Change A List	AQ
30/11/22	Otsuka Medical Devices and ReCor Medical Announce Submission of Application for Pre-Market Approval of the Paradise Ultrasound Renal Denervation System to the U.S. Food and Drug Administration	AQ
06/11/22	ReCor Medical Announces Consistent Reduction of Blood Pressure in Pooled Analysis of Three Clinical Trials at AHA 2022	BU
20/09/22	Otsuka Medical Devices Announces Results of RADIANCE II Pivotal Trial at TCT 2022 Annual Meeting	AQ
18/09/22	ReCor Medical Announces Results of RADIANCE II Pivotal Trial at TCT 2022 Annual Meeting	BU
14/09/22	ReCor Medical to Present RADIANCE II US Pivotal Trial Data in Late-Breaking Presentation at TCT Conference	BU
29/07/22	Otsuka : Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending December 31, 2022	PU
26/07/22	Otsuka : Notice Regarding Revisions of Consolidated Results Forecast for the first half of FY2022	PU
26/07/22	Otsuka : Medical Devices Announces Primary Endpoint Met in the RADIANCE II US Pivotal Trial of the Paradise System for the Treatment of Hypertension	PU
27/06/22	Otsuka : and Lundbeck announce positive results showing reduced agitation in patients with Alzheimer’s dementia treated with brexpiprazole	PU
28/04/22	Otsuka : Notice Concerning Completion of Payment for Disposal of Treasury Shares as Restricted Stock Compensation	PU
21/04/22	Otsuka : Consolidated Financial Statements for the fiscal year ended December 31, 2021	PU
21/04/22	Otsuka Group Joins RE100 International Initiative - Comitted to 100% Renewable Energy	AQ
31/03/22	Otsuka : Akebia Therapeutics Receives Complete Response Letter from U.S. FDA for Vadadustat for the Treatment of Anemia associated with Chronic Kidney Disease	PU
30/03/22	Otsuka : Notice Concerning Disposal of Treasury Shares as Restricted Stock Compensation	PU